NIH
61 - 80 of 164 Results
-
-
A Very Good Night for Abortion Rights Backers
Episode 322Abortion rights backers won major victories in at least five states in the 2023 off-year elections Nov. 7, proving the staying power of abortion as a political issue in the wake of the Supreme Courtâs 2022 decision overturning Roe v. Wade. Meanwhile, the National Institutes of Health finally has a new director, after Democrats temporarily blocked President Joe Bidenâs nominee over a mostly unrelated fight about prescription drug prices. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join Ńîšóĺú´ŤĂ˝Ňîl Health Newsâ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Ńîšóĺú´ŤĂ˝Ňîl Health Newsâ Julie Appleby, who reported and wrote the latest âBill of the Monthâ feature.
The New Speakerâs (Limited) Record on Health
Episode 320The House finally has a new speaker: Mike Johnson (R-La). Heâs a relative newcomer whoâs been a lower-level member of the House GOP leadership. And while heâs an outspoken opponent of abortion and same-sex marriage, his record on other health issues is scant. Meanwhile, the National Institutes of Health appears on track to be getting a new director, and Georgiaâs Medicaid work requirement experiment is off to a very slow start. Alice Miranda Ollstein of Politico and Rachel Cohrs of Stat join Ńîšóĺú´ŤĂ˝Ňîl Health Newsâ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Michael Cannon, director of health policy studies at the Cato Institute, a libertarian think tank.
-
Postcard from Capitol Hill
Biden Pick to Lead NIH Finally Has Her Day, but Still Gets Caught Up in Drug Price Debate
Monica Bertagnolli, the presidentâs choice to head the National Institutes of Health, appeared before a Senate committee this week. Her confirmation has been held up by Sen. Bernie Sanders (I-Vt.), who has demanded President Joe Biden work more aggressively to lower prescription drug prices.
-
The NIH Ices a Research Project. Is It Self-Censorship?
The National Institutes of Health appeared to be digging into health misinformation. But then the federal agency stepped back. It canât quite explain why, sometimes even offering contradictory explanations.
By Darius Tahir Congress Is Out. The Presidential Campaign Is In.
Episode 308Congress is in recess until after Labor Day, and lawmakers wonât have much time when they return to get the government funded before the next fiscal year. Meanwhile, the Republican campaign for president has begun in earnest, and while repealing the Affordable Care Act is no longer the top promise, some candidates have lively ideas about what to do with federal health programs. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Lauren Weber of The Washington Post join Ńîšóĺú´ŤĂ˝Ňîl Health Newsâ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews Ńîšóĺú´ŤĂ˝Ňîl Health Newsâ Phil Galewitz, who reported the latest Ńîšóĺú´ŤĂ˝Ňîl Health News-NPR âBill of the Month,â about how a bill that should never have been sent created headaches for one patient.
Letâs Talk About the Weather
Episode 306Itâs been the summer of broken weather records around the world â for heat, rain, and wildfire smoke â advertising the risks of climate change in a big way. But, apparently, itâs not enough to break the logjam in Washington over how to address the growing climate crisis. Meanwhile, in Texas, women who were unable to get care for pregnancy complications took their stories to court, and Congress gears up to â maybe â do something about prescription drug prices. Alice Miranda Ollstein of Politico, Shefali Luthra of The 19th, and Rachel Cohrs of Stat join Julie Rovner, Ńîšóĺú´ŤĂ˝Ňîl Health Newsâ chief Washington correspondent, to discuss these issues and more. Also this week, Rovner interviews Meena Seshamani, the top administrator for the federal Medicare program.
-
Watch: Going Beyond the Script of âThe G Wordâ and How Government Responds to Disease (Or Not)
KHN Editor-in-Chief Elisabeth Rosenthal joins comedian Adam Conover to discuss his new Netflix series, âThe G Word,â which examines the federal government's role in Americans' lives, and how it plays out in the covid era.
-
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
By Arthur Allen -
KHNâs âWhat the Health?â: Funding for the Next Pandemic
In his proposed budget, President Joe Biden called for a boost in health spending that includes billions of dollars to prepare for a future pandemic. But that doesnât include money he says is needed immediately for testing and treating covid-19. Also this week, federal regulators authorized a second booster shot for people 50 and older yet gave little guidance to consumers about who needs the shot and when. Amy Goldstein of The Washington Post, Jennifer Haberkorn of the Los Angeles Times, and Rachana Pradhan of KHN join KHNâs Mary Agnes Carey to discuss these issues and more. Plus, Julie Rovner interviews KHNâs Julie Appleby, who reported and wrote the latest KHN-NPR âBill of the Monthâ episode about a very expensive air ambulance ride.
-
KHNâs âWhat the Health?â: Congress Shelves Covid Funding for Now
The Biden administrationâs request for billions more in funding to fight covid-19 hit a snag on Capitol Hill this week, as Democrats objected to Republican demands that money allocated to states but not yet spent be reclaimed. Meanwhile, the big annual spending bill about to cross the finish line addresses other health policy changes, such as giving the FDA authority to regulate âsyntheticâ nicotine. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Cohrs of Stat, and Jessie Hellmann of Modern Healthcare join KHNâs Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
Why Pregnant People Were Left Behind While Vaccines Moved at âWarp Speedâ to Help the Masses
Clinical trials of covid-19 vaccines excluded pregnant people, which left many women wondering whether to get vaccinated.
By Liz Szabo -
Q&A
Wartime Trauma Hits Close to Home for Scholar of Dementia
The federal government is putting up $7.2 million for a study into the correlation between war trauma and dementia in Vietnamese immigrants. Oahn Meyer, an associate professor at the University of California-Davis who is leading the study, wonders whether her motherâs dementia is linked to trauma she suffered during the Vietnam War.
-
KHNâs âWhat the Health?â: Abortion Politics Front and Center
The polarizing abortion issue threatens to tie up Congress, the Supreme Court and the states for the coming year. Meanwhile, Congress kicks the can down the road to December on settling its spending priorities. Joanne Kenen of Politico and the Johns Hopkins School of Public Health, Yasmeen Abutaleb of The Washington Post and Sarah Karlin-Smith of the Pink Sheet join KHNâs Julie Rovner to discuss these issues and more.
Also this week, Rovner interviews KHNâs Aneri Pattani, who delivered the latest KHN-NPR âBill of the Monthâ episode about a covid test that cost as much as a luxury car. -
Collinsâ Skillful Piloting Helped NIH Steer Clear of Political Minefields
Dr. Francis Collins, who announced he is stepping down as chief of the National Institutes of Health, used his communication skills and political insights to help protect the highly acclaimed federal research institutes through difficult times.
By Julie Rovner -
Who Qualifies for a Covid Booster? The List Is Growing Longer
KHNâs Sarah Jane Tribble and Arthur Allen join Science Friday host Ira Flatow to recap the evolving news in the run-up to offering booster shots for the covid vaccine.
-
How Fauci and the NIH Got Ahead of the FDA and CDC in Backing Boosters
With real-time data streaming in from highly specialized researchers in the U.S. and abroad, NIH scientists became convinced that boosting the covid-19 vaccine was needed to save lives, prompting the president to announce a plan with a Sept. 20 start date. Scientists at the regulatory agencies werenât yet convinced. A meeting Friday will determine what happens next. Hereâs the story from behind the scenes.
By Sarah Jane Tribble and Arthur Allen -
Microbiome Startups Promise to Improve Your Gut Health, but Is the Science Solid?
A raft of startups are charging consumers hundreds of dollars to analyze the microbes in their gut and offer dietary advice based on the results. But scientists say scant research has been done, and as customers of one company have learned the hard way, the experience isnât always smooth.
-
Paying Billions for Controversial Alzheimerâs Drug? How About Funding This Instead?
Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.